zevorcabtagene autoleucel (CT053) / CARsgen, Huadong Medicine - LARVOL DELTA

Dynamic Targetable Surface Proteins on Extracellular Vesicles for Monitoring Depth of Response and Predicting Survival in Relapsed/Refractory Multiple Myeloma Treated with CAR T-Cell Therapy (USCAP 2026) - "(%) 7 (15.6) Myeloma subtype, n (%) IgG 21 (46.7) IgA 8 (17.8) IgD 3 (6.7) Kappa 5 (11.1) Lambda 7 (15.6) Non secretory 1 (2.2) Durie-Salmon stage, n (%) I 5 (11.1) II 4 (8.9) III 36 (80.0) R-ISSb, n (%) I 7 (16.3) II 30 (69.8) III 6 (13.9) High-risk cytogeneticsc, n (%) 0 29 (67.4) 1 10 (23.3) 2 4 (9.3) Triple-exposured, n (%) 12 (26.7) Penta-exposuree, n (%) 10 (22.2) Previous autologous stem cell transplantation, n (%) 12 (26.7) Previous CAR-T therapy, n (%) 2 (4.4) Bridging therapyf, n (%) 21 (46.7) BCMA expression on plasma cells at baseline, median (IQR) 82.9 (63.1-95.4) BCMA CAR-T products, n (%) Equecabtagene Autoleucel Academic CAR-T cells Zevorcabtagene Autoleucel 41 (91.1) 3 (6.7) 1 (2.2) CRS, n (%) 0-1 39 (86.7) 2-4 6 (13.3) ICANS, n (%) 0 (0.0) BCMA, B-Cell Maturation Antigen; CAR, Chimeric Antigen Receptor; CRS, Cytokine Release Syndrome; EMMR-ISS, Revised International Staging System; DS, Durie-Salmon; ICANS, Immune Effector Cell-Associated Neurotoxicity..."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Inflammation • Multiple Myeloma • SLAMF7

Financial Highlights (The Manila Times) - "CARsgen's revenue was around RMB125.7 million for the year ended December 31, 2025 mainly from zevor-cel, autologous BCMA CAR T-cell product in which the primary revenue of zevor-cel was calculated on the basis of ex-works price, rather than on the basis of end-of-market prices."

Commercial • Multiple Myeloma

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma. (PubMed, Hematol Oncol) - "To date, four B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies have been approved in the United States and China for the treatment of R/R MM: idecabtagene vicleucel, ciltacabtagene autoleucel, equecabtagene autoleucel, and zevorcabtagene autoleucel...In this review, we compare the efficacy and safety of these four approved BCMA-directed CAR T-cell therapies. We also discuss potential factors underlying the observed differences and highlight strategies that may further improve the clinical outcomes of this revolutionary therapy."

Clinical • Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma. (PubMed, Exp Hematol Oncol) - "Zevor-cel induces deep and durable responses in heavily pre-treated RRMM patients with a manageable safety profile."

Journal • P2 data • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai (PRNewswire) - "With a total investment amount not exceeding RMB370 million, the Company will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai. This move closely aligns with the commercialization progress of the Company's multiple CAR T-cell products, including the marketed product zevorcabtagene autoleucel and the CAR T-cell product satricabtagene autoleucel (R&D code 'CT041') for solid tumor currently in the NDA stage. It also lays the foundation for the future mass production of multiple allogeneic CAR T-cell products (such as CT0596 and CT1190B)."

Licensing / partnership • Hematological Malignancies • Multiple Myeloma • Solid Tumor

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma (ASH 2023) - P1/2 | "Introduction: Phase 1b of LUMMICAR STUDY 1 was conducted in China (NCT03975907) for zevorcabtagene autoleucel (zevor-cel, CT053), a fully human autologous chimeric antigen receptor (CAR) T-cell therapy comprising a B-cell maturation antigen-specific single-chain variable fragment, in patients with relapsed or refractory multiple myeloma (RRMM)... At approximately 3 years of follow-up, heavily pre-treated RRMM patients maintained deep and durable responses after receiving a single infusion of zevor-cel, which showed a well-managed safety profile in the ongoing long-term follow-up."

Clinical • P1 data • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology

Zevor-Cel Shows Long-Term Efficacy in Small R/R Multiple Myeloma Population (Cancer Network) - "After a median follow-up of 53.3 months (range, 14.8-63.5), data showed an objective response rate (ORR) of 100% (95% CI, 76.8%-100.0%), with 66.7% (n = 2/3; 95% CI, 9.4%-99.2%) of those receiving 100 x 106 cells of zevor-cel achieving a complete response (CR) or stringent CR (sCR) compared with 81.8% (n = 9/11; 95% CI, 48.2%-97.7%) of those who received the agent at 150 x 106 cells. In each respective dosing cohort, the very good partial response (VGPR) rates were 100% (n = 3/3; 95% CI, 29.2%-100.0%) and 90.9% (n = 10/11; 95% CI, 58.7%-99.8%), the median progression-free survival (PFS) was not evaluable (NE; 95% CI, 3.7-NE) and 24.7 months (95% CI, 14.9-NE), and the median PFS among those with a CR or better was NE (95% NE-NE) and 26.91 months (95% CI, 15.1-NE)."

P1 data • Multiple Myeloma

CARsgen Therapeutics Holdings Limited and Dispatch Bio have announced a clinical collaboration to test a novel combination therapy for solid tumors, with a Phase 1 trial slated to begin in China in 2026. (Indian Pharma Post) - "The study will evaluate DISP-11, an investigational therapy combining Dispatch Bio’s first-in-class Flare platform—including the novel tumor-specific virus DV-10—with CARsgen’s zevorcabtagene autoleucel....The trial will focus on patients with epithelial-origin solid tumors, which make up 90% of all solid tumors. Participants will first receive DV-10, followed by administration of zevor-cel."

Commercial • New P1 trial • Solid Tumor

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma (ASH 2025) - "He received induction therapy with the PAD regimen (bortezomib, liposomal doxorubicin, dexamethasone) and DKd regimen (daratumumab, carfilzomib, dexamethasone), achieving a Very Good Partial Response (VGPR)...Maintenance therapy with the KP regimen (carfilzomib, pomalidomide) was administered, during which surveillance studies showed minimal residual disease (MRD) negativity by bone marrow flow cytometry and negative serum and urine immunofixation electrophoresis...Bridging therapy was initiated the following day (February 23, 2025) with Aponermin (10mg/kg on Days 1-5), Selinexor (40mg once weekly), and dexamethasone (20mg once weekly)...The regimen did not adversely impact hematologic recovery following CAR-T cell infusion, and cytokine release syndrome (CRS) was mild and manageable. For patients with triple-class refractory (TCR) or penta-drug refractory multiple myeloma undergoing CAR-T cell therapy, Aponermin-based regimen represents a viable and well-tolerated..."

CAR T-Cell Therapy • Bone Marrow Transplantation • Hematological Malignancies • Inflammation • Multiple Myeloma

CARsgen Therapeutics Holdings Limited...today announced...zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the 'Innovative Drug Catalogue') for the treatment of relapsed/refractory multiple myeloma. (The Manila Times)

Reimbursement • Multiple Myeloma

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2024) - P1/2 | "Zevorcabtagene autoleucel (zevor‑cel) is a fully human, BCMA-targeting autologous CAR T-cell therapy...There was a trend towards favorable outcomes which was seen in patients without high-risk cytogenetics compared to those with high-risk cytogenetics : 18m DOR rate of 66% versus 58%, 18m PFS rate of 69% versus 56% and an estimated 30m OS rate of 85% versus 76%, however, none of these differences were statistically significant. Conclusion The subgroup analyses of the pivotal Phase II stage of LUMMICAR STUDY 1 indicated that the clinical efficacy of zevor‑cel is not significantly impacted by baseline characteristics suggesting that even patients with RRMM with poor prognostic factors may benefit from zevor-cel."

CAR T-Cell Therapy • Clinical • P2 data • Hematological Malignancies • Multiple Myeloma • Oncology

Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma. (PubMed, Blood Adv) - P1/2 | "Zevorcabtagene autoleucel (zevor-cel or CT053) is a fully human BCMA targeting CAR T therapy for patients with RRMM...This 53.3-months median follow-up data of zevor-cel reaffirms the initial results with a manageable safety profile and compelling efficacy in RRMM. NCT03975907."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 (PRNewswire) - "In this study, a total of 14 patients with relapsed or refractory multiple myeloma (R/R MM) received a single infusion of zevor-cel....The overall response rate was 100% (95% CI: 76.8, 100.0) with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR)....The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (OS) was not reached. The proportion of patients surviving at 24, 36, 48 and 60 months after infusion were 100%, 92.3%, 84.6% and 76.9%, respectively."

P1 data • Multiple Myeloma

Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma (IMS 2025) - P1/2 | "At approximately 5 years of follow-up, zevor-cel demonstrates manageable safety profile while eliciting deep and durable responses in RRMM patients."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China (PRNewswire) - "CARsgen Therapeutics...announces reaching agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership) ('Zhuhai SB Xinchuang') to jointly invest in UCARsgen Biotech Limited ('UCARsgen')....Under the agreements, UCARsgen has secured the exclusive rights in mainland China for the research, development, manufacture, and commercialization of the following allogeneic CAR-T products from CARsgen Therapeutics: the BCMA-targeted allogeneic CAR-T cell therapy for the treatment of multiple myeloma and plasma cell leukemia and the CD19/CD20 dual-targeted allogeneic CAR-T cell therapy for the treatment of B-cell malignancies."

Licensing / partnership • Hematological Malignancies • Multiple Myeloma

Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy (clinicaltrials.gov) - P=N/A | N=1500 | Not yet recruiting | Sponsor: CARsgen Therapeutics Co., Ltd.

New trial • Hematological Malignancies • Multiple Myeloma • Oncology

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma (PRNewswire) - P1/2 | N=121 | LUMMICAR STUDY 1 (NCT03975907) | Sponsor: CARsgen Therapeutics Co., Ltd. | "CARsgen Therapeutics Holdings Limited...announces that the Company will present the clinical data of zevorcabtagene autoleucel...at the 66th Annual Congress of the American Society of Hematology....In 102 patients with RRMM who had received at least 3 prior lines of therapy including an immunomodulatory drug and a proteasome inhibitor, the objective response rate (ORR) was 92.2%, the stringent complete response (sCR) or complete response (CR) was 71.6%. The ORR or the CR/sCR rate was not affected by any of the baseline characteristics tested. With a median follow-up of 20.3 (range: 0.4 to 27) months, the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) data were not mature and therefore, 18-month (18m) and estimated 30-month (30m) event free rates were used as efficacy outcomes for subgroup analyses."

P2 data • Multiple Myeloma

CARsgen U.S. Clinical Holds Lifted by FDA (PRNewswire) - "CARsgen Therapeutics Holdings Limited...announces that the U.S. Food and Drug Administration ('FDA') lifted the clinical holds on clinical trials of zevorcabtagene autoleucel (zevor-cel, CT053, an autologous CAR-T product against BCMA), satricabtagene autoleucel (satri-cel, CT041, an autologous CAR-T product against Claudin18.2), and CT071 (an autologous CAR-T product against GPRC5D) in the United States."

FDA event • Hematological Malignancies • Oncology

A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: CARsgen Therapeutics Co., Ltd.

New trial • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

VOLUNTARY ANNOUNCEMENT TO PRESENT ZEVORCABTAGENE AUTOLEUCEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS (HKEXnews) - "The board of directors of the Company...announces that the Company will present the clinical data of zevorcabtagene autoleucel...CT071 (an autologous CAR T-cell therapy candidate targeting GPRC5D), and CT0590 (an allogeneic CAR T-cell product candidate against BCMA) at the 66th Annual Congress of the American Society of Hematology ('ASH'). Abstracts and further details will be announced after November 5, 2024 Eastern Time."

Clinical data • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology

CARsgen Submitted Application to Request Lifting Clinical Holds to FDA (CARsgen Press Release) - "CARsgen Therapeutics Holdings Limited...announces that the U.S. Food and Drug Administration ('FDA') recently did a follow-up inspection of the manufacturing site located in Durham, North Carolina. The inspection was positive, and no observation (Form 483) was issued. The Company has submitted the complete response letters to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 to FDA on October 4, 2024. FDA is expected to respond within 30 calendar days."

FDA event • Oncology

CARsgen Announces 2024 Interim Results (PRNewswire) - "CARsgen has been collaborating with Huadong Medicine for the commercialization of zevor-cel in mainland China. As of July 31, 2024, zevor-cel had been included in nearly 20 provincial or municipal government-subsidized insurance programs and private health insurance products; certification and regulatory filings had been completed in over 100 healthcare institutions across 19 provinces or cities nationwide; we had received a total of 52 orders from Huadong Medicine...The Group's revenue was over RMB6 million for the six months ended June 30, 2024 mainly from zevor-cel in which the primary revenue of zevor-cel was calculated on the basis of ex-works price, rather than on the basis of end-of-market prices....Besides, the Company received a milestone payment of RMB75 million from Huadong Medicine for zevor-cel for the six months ended June 30, 2024....Data updates for CT071 and CT0590 are to be disclosed in the second half of 2024."

Clinical data • Commercial • Hematological Malignancies • Multiple Myeloma • Oncology

Keji Pharmaceutical-B (2171.HK): CARsgen plans to list CT041 and submit an NDA in the first half of 2025 [Google translation] (FUTU) - "CT041 is a potential global first-of-its-kind autologous CAR-T candidate targeting CLDN 18.2...it is planned to submit an NDA to the NMPA in the first half of 2025....With CT053 and CT041 approved for listing, we expect the company's revenue for 2024-2026 to be 100 million yuan, 300 million yuan, and 700 million yuan, respectively."

China filing • Commercial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

CARsgen Presents Phase II Results on Zevorcabtagene Autoleucel and First-in-human CT071 Results at EHA 2024 [Google translation] (CARsgen Press Release) - "CARsgen Therapeutics...announces that the updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association...The results of LUMMICAR STUDY 1 of zevorcabtagene autoleucel were reported as an oral presentation at the 29th EHA Annual Congress on June 15, 2024, 17:30-17:45 CEST....The preliminary results of Phase I of CT071 were presented as a poster at the 29th EHA Annual Congress on June 14, 2024, 18:00 - 19:00 CEST..."

Clinical data • Hematological Malignancies • Multiple Myeloma • Oncology

The research results of Keji Pharmaceutical's Xikaize Phase II clinical trial and CT071 first-in-human trial were unveiled at the 2024 EHA [Google translation] (Pharm News) - P1/2 | N=121 | LUMMICAR STUDY 1 (NCT03975907) | Sponsor: CARsgen Therapeutics Co., Ltd. | "The results of the zevor-cel LUMMICAR STUDY 1 study were presented orally at the 29th EHA Annual Meeting on June 15, 2024, at 17:30-17:45 CEST...Right off the bat Early start-up operation of the phase II cohort (n=102) of the phase I/II study LUMMICAR-1 in R/R MM who had received at least 3 lines of previous treatment and with acceptable safety...92.2% of people interested in investigating the plan (ORR), 73 people in the group (71.6%) (sCR, n= 70) After completion (CR, n=3)....The PFS of all patients at 12 and 18 months was 76.3% (95% CI: 66.45, 83.56) 61.9% (95% CI: 51.19, 70.85) 90.2% of people (95% CI: 82.55, 94.60) and 79.4% (95% CI: 69.69, 86.29). 8.66) and 87.7% (95% CI: 76.56, 93.77)."

P2 data • Hematological Malignancies • Multiple Myeloma • Oncology